Abemaciclib Beneficial for HR & #43;, HER2 & #8722; Early Breast Cancer
TUESDAY, Oct. 6, 2020 -- For patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 −), high-risk early breast cancer (EBC), the addition of abemaciclib to endocrine therapy (ET) increases the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | HER2 | Hormones | Pharmaceuticals